RELAY, Erlotinib Plus Ramucirumab in Untreated, EGFR-Mutated, Metastatic NSCLC: Outcomes by EGFR Exon 19 Deletion Variants

By sjmartinez • February 2, 2024

Nishino K, Shih JY, Nakagawa K, Reck M, Garon EB, Carlsen M, Matsui T, Visseren-Grul C, Nadal E. RELAY, Erlotinib Plus Ramucirumab in Untreated, EGFR-Mutated, Metastatic NSCLC: Outcomes by EGFR Exon 19 Deletion Variants. JTO Clin Res Rep. 2023 Dec 19;5(2):100624. doi: 10.1016/j.jtocrr.2023.100624. PMID: 38304857; PMCID: PMC10832259.

Tags: Carcinoma, EGFR exon 19 deletion variant, Hematology/Oncology, Non–small cell lung, Publications, ramucirumab, targeted therapy, VEGFR inhibition

Navigating Complexity: A Case Study on Hemophagocytic Lymphohistiocytosis Diagnosis and Management Challenges

Nguyen J, Tun N, Burley N, Bolos D. Navigating Complexity: A Case Study on Hemophagocytic Lymphohistiocytosis Diagnosis and Management Challenges. Cureus. 2024 May 4;16(5):e59628. doi:[...]

Unusual painful pelvic masses: Extramedullary hematopoiesis with extramedullary multiple myeloma

Cai J, Varda M, Sin D, Overby H, Yeh JJ. Unusual painful pelvic masses: Extramedullary hematopoiesis with extramedullary multiple myeloma. Clin Case Rep. 2024 May[...]

Generalizability of PGS313 for breast cancer risk in a Los Angeles biobank

Shang H, Ding Y, Venkateswaran V, Boulier K, Kathuria-Prakash N, Malidarreh PB, Luber JM, Pasaniuc B. Generalizability of PGS313 for breast cancer risk in a Los[...]